New drug combo aims to fight spread of prostate cancer

NCT ID NCT07140900

Recruiting now Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This early-phase trial is testing a new immunotherapy drug called xaluritamig combined with standard hormone therapies (darolutamide or abiraterone) in 60 men with metastatic hormone-sensitive prostate cancer. The main goal is to check safety and tolerability, while also looking at how well the combination controls the cancer. The study is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: xaluritamig (a type of immunotherapy) combined with darolutamide or abiraterone (hormone-blocking drugs)
What this could lead to: If it works, this could lead to a more effective treatment option for men with metastatic hormone-sensitive prostate cancer.
What could go wrong: This is an early Phase 1b trial with only 60 participants, focused on safety. It is too soon to know if the combination will be effective or have manageable side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Cabrini Hospital
RECRUITING

Clayton, Victoria, 3168, Australia
Calvary Mater Newcastle Hospital
RECRUITING

Waratah, New South Wales, 2298, Australia
Centre Hospitalier Universitaire Vaudois
RECRUITING

Lausanne, 1011, Switzerland
Chris OBrien Lifehouse
RECRUITING

Camperdown, New South Wales, 2050, Australia
Cleveland Clinic Foundation
RECRUITING

Cleveland, Ohio, 44195, United States
Dana Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
Kantonsspital Graubuenden
RECRUITING

Chur, 7000, Switzerland
Kantonsspital Sankt Gallen
RECRUITING

Sankt Gallen, 9007, Switzerland
Peter MacCallum Cancer Centre
RECRUITING

Melbourne, Victoria, 3000, Australia
Sarah Cannon Research Institute
RECRUITING

Nashville, Tennessee, 37203, United States
South Texas Accelerated Research Therapeutics - Carolinas
RECRUITING

Myrtle Beach, South Carolina, 29572, United States
The Alfred Hospital
RECRUITING

Melbourne, Victoria, 3004, Australia
Thomas Jefferson University
RECRUITING

Philadelphia, Pennsylvania, 19107, United States
University of California San Francisco
RECRUITING

San Francisco, California, 94158, United States
University of Minnesota
RECRUITING

Minneapolis, Minnesota, 55455, United States
University of Pittsburgh Medical Center Hillman Cancer Center
RECRUITING

Pittsburgh, Pennsylvania, 15232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.